Inventor · disambiguated record
Gillian Payne
Also filed as: PAYNE GILLIAN
19 granted patents·11 pending applications·413 citations·filing 2003–2025
96Inventor score
Top patents by PatentIndex Score
30 records- 0197US10752683B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2019·Granted Aug 25, 2020·13 cites·31 claims
- 0297US9670279B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·26 cites·118 claims
- 0397US9133275B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2013·Granted Sep 15, 2015·45 cites·44 claims
- 0496US9670280B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·19 cites·74 claims
- 0596US9670278B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·18 cites·104 claims
- 0696US9657100B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted May 23, 2017·16 cites·40 claims
- 0796US9598490B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Mar 21, 2017·18 cites·40 claims
- 0896US8557966B2Folate receptor 1 antibodies and immunoconjugates and uses thereofAB OLGA·Filed 2011·Granted Oct 15, 2013·89 cites·20 claims
- 0995US11135305B2Methods for increasing efficacy of FOLR1 cancer therapyIMMUNOGEN INC·Filed 2017·Granted Oct 5, 2021·9 cites·28 claims
- 1093US10301385B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2017·Granted May 28, 2019·8 cites·28 claims
- 1193US8790649B2EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jul 29, 2014·26 cites·37 claims
- 1292US8709432B2Methods for increasing efficacy of FOLR1 cancer therapyCARRIGAN CHRISTINA N·Filed 2012·Granted Apr 29, 2014·42 cites·45 claims
- 1392US7834155B2CA6 antigen-specific cytotoxic conjugate and methods of using the sameIMMUNOGEN INC·Filed 2005·Granted Nov 16, 2010·13 cites·21 claims
- 1491US7202346B2Antibodies to non-shed Muc1 and Muc16, and uses thereofIMMUNOGEN INC·Filed 2003·Granted Apr 10, 2007·62 cites·37 claims
- 1589US2024132585A1Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2023·Application pending·0 cites
- 1685US10603388B2Methods for formulating antibody drug conjugate compositionsIMMUNOGEN INC·Filed 2017·Granted Mar 31, 2020·5 cites·7 claims
- 1780US9125896B2EGFR-binding molecules and immunoconjugates thereofIMMUNOGEN INC·Filed 2013·Granted Sep 8, 2015·3 cites·39 claims
- 1876US2022143208A1Methods for increasing efficacy of folr1 cancer therapyIMMUNOGEN INC·Filed 2021·Application pending·0 cites
- 1975US2021032327A1Folate Receptor 1 Antibodies and Immunoconjugates and Uses ThereofIMMUNOGEN INC·Filed 2020·Application pending·0 cites
- 2075US2025228960A1Methods for increasing efficacy of folr1 cancer therapyIMMUNOGEN INC·Filed 2025·Application pending·0 cites
- 2172US9370584B2CA6 antigen-specific cytotoxic conjugate and methods of using the samePAYNE GILLIAN·Filed 2010·Granted Jun 21, 2016·1 cites·90 claims
- 2272US2023364252A1Methods for formulating antibody drug conjugate compositionsIMMUNOGEN INC·Filed 2022·Application pending·0 cites
- 2368US2018127511A1CA6 Antigen-Specific Cytotoxic Conjugate and Methods of Using the SameSANOFI SA·Filed 2017·Application pending·0 cites
- 2466US9822183B2CA6 antigen-specific cytotoxic conjugate and methods of using the sameIMMUNOGEN INC·Filed 2016·Granted Nov 21, 2017·0 cites·20 claims
- 2565US8987424B2CA6 antigen-specific cytotoxic conjugate and methods of using the samePAYNE GILLIAN·Filed 2008·Granted Mar 24, 2015·0 cites·71 claims
- 2661US2014363453A1Methods for Increasing Efficacy of FOLR1 Cancer TherapyIMMUNOGEN INC·Filed 2014·Application pending·0 cites
- 2755US2019365917A1Methods for formulating antibody drug conjugate compositionsIMMUNOGEN INC·Filed 2019·Application pending·0 cites
- 2850US2016058884A1Methods for formulating antibody drug conjugate compositionsIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 2948US2016060345A1Novel EGFR-Binding Molecules and Immunoconjugates ThereofIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 3046US2005123549A1CA6 antigen-specific cytotoxic conjugate and methods of using the sameIMMUNOGEN INC·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →